长链非编码 RNA NR2F1-AS1 作为癌症患者预后的潜在生物标志物：荟萃分析和生物信息学分析。

LncRNA NR2F1-AS1 as a potential biomarker for prognosis in cancer patients: meta and bioinformatics analysis.

机构信息

Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China.

Anesthesiology and Critical Care Medicine Key Laboratory of Luzhou, Southwest Medical University, Luzhou, Sichuan Province, China.

出版信息

Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1263-1272. doi: 10.1080/14737159.2023.2277521. Epub 2023 Dec 15.

DOI:10.1080/14737159.2023.2277521

PMID:37902251

Abstract

BACKGROUND

Previous studies have shown that the differential expression of lncRNA NR2F1-AS1 is closely related to the prognosis of cancer, but the conclusion is still controversial. Therefore, we conducted a meta-analysis and bioinformatics analysis to explore the correlation between LncRNA NR2F1-AS1 and cancer prognosis.

METHODS

From the beginning to January 25, 2023, we searched for correlational studies on PubMed, Embase, the Cochrane Library, and Web of Science. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the importance of LncRNA NR2F1-AS1 for survival and clinicopathological features of human cancers.

RESULTS

The meta-analysis of 637 patients in the 11 included articles showed that upregulation of LncRNA NR2F1-AS1 was associated with shorter overall survival (HR = 1.46,95%Cl 1.06-2.01, = 0.02) in cancer patients. In addition, overexpression of LncRNA NR2F1-AS1 predicted TNM tumor stage (OR = 3.37, 95%Cl 2.07-5.48, < 0.00001), and Distant metastasis (OR = 0.18, 95%Cl 0.06-0.48, = 0.0007). However, the difference in age (OR = 1.10,95%Cl 0.71-1.71, = 0.67), gender (OR = 1.26,95%Cl 0.79-2.00, = 0.34), Lymph node metastasis (OR = 1.44,95%Cl 0.27-7.80, = 0.67) or larger tumor size (OR = 1.56,95%Cl 0.48-5.08, = 0.46) was not statistically significant.

CONCLUSION

Upregulation of LncRNA NR2F1-AS1 was associated with poor prognosis and advanced clinicopathologic features of tumor patients.

摘要

背景

先前的研究表明，lncRNA NR2F1-AS1 的差异表达与癌症的预后密切相关，但结论仍存在争议。因此，我们进行了荟萃分析和生物信息学分析，以探讨 LncRNA NR2F1-AS1 与癌症预后的相关性。

方法

从开始到 2023 年 1 月 25 日，我们在 PubMed、Embase、Cochrane 图书馆和 Web of Science 上搜索了相关的相关性研究。我们使用合并的风险比（HR）和优势比（OR）及其 95%置信区间（CI）来确定 LncRNA NR2F1-AS1 对人类癌症的生存和临床病理特征的重要性。

结果

纳入的 11 项研究中的 637 名患者的荟萃分析表明，LncRNA NR2F1-AS1 的上调与癌症患者的总生存期更短相关（HR=1.46，95%Cl 1.06-2.01， =0.02）。此外，LncRNA NR2F1-AS1 的过表达预测了 TNM 肿瘤分期（OR=3.37，95%Cl 2.07-5.48， <0.00001）和远处转移（OR=0.18，95%Cl 0.06-0.48， =0.0007）。然而，年龄（OR=1.10，95%Cl 0.71-1.71， =0.67）、性别（OR=1.26，95%Cl 0.79-2.00， =0.34）、淋巴结转移（OR=1.44，95%Cl 0.27-7.80， =0.67）或肿瘤较大（OR=1.56，95%Cl 0.48-5.08， =0.46）的差异无统计学意义。